Corify Care, a cardiac mapping startup supported by EIT Health, achieves CE Marking

• Corify Care has developed a technology to diagnose and treat cardiac arrhythmias: ACORYS, which allows clinicians to see the heart’s electrical activity in real-time.
•  The Spanish start-up achieves the CE marking for the solution under the new European Medical Device Regulation (MDR).
•  EIT Health has supported Corify Care since its very beginning, with acceleration programmes and funding of over €2.5 million.

After 7 years of support from EIT Health, the Spanish start-up Corify Care has achieved the CE marking for ACORYS, its innovative arrhythmia mapping technology.  EIT Health Spain Foundation, a Co-Location Centre of EIT Health, which is part of the European Institute of Innovation and Technology (EIT), a body of the European Union, is proud to have successfully detected the potential of Corify Care, whose innovation will now be accessible to patients with cardiac arrhythmias across Europe.

“ACORYS is a clear example of how the EIT Health Spain Foundation can help start-ups navigate the regulatory path and reach key market access milestones. The ultimate goal is for innovative solutions to reach clinicians and patients more quickly and, as early as possible, to impact positively on the diagnosis and treatment of the diseases,” says Izabel Alfany, the entity’s Managing Director. “It is very satisfying to see how they have made the most of the support offered by EIT Health,” she adds.

EIT Health has supported the project from the early stages: the startup participated in two EIT Health accelerator programmes aimed at helping start-ups develop their potential. In 2020, EIT recognised Corify Care’s technology as the most innovative in Europe. Following this recognition, in 2021 Corify Care made a significant leap forward with a private investment round of €2.3 million. Since 2022, EIT Health has continued to be an integral part of Corify Care’s journey, funding the SAVE-COR (ACORYS) project with over €2.5 million.

Achieving CE marking was the next key objective on this journey and has been made possible by evidence gathered in several clinical studies conducted as part of the SAVE-COR project (funded and supported by EIT Health) in referral hospitals in Spain and Portugal. These studies, involving over 1,000 patients, demonstrated the critical need for this innovative technology.

What makes this innovation so necessary?

Cardiac arrhythmias, such as atrial fibrillation, affect millions of people worldwide and pose significant health risks, such as strokes or heart failure. It is estimated that by 2060, 17.9 million people in Europe will suffer from atrial fibrillation, the most common type of arrhythmia ⁽¹⁾. Traditional cardiac mapping methods are often invasive, slow, and uncomfortable for patients.

The ACORYS mapping system addresses these issues by providing a non-invasive, quick, and precise method to map the heart’s electrical activity, eliminating the need for CT or MRI scans. By using body surface potential measurements and a 3D torso model, ACORYS generates highly detailed electro-anatomical maps of the heart, that allow clinicians to observe the electrical activity of this muscle in real time, enhancing their ability to diagnose and treat cardiac arrhythmias with unparalleled accuracy.

The recent CE marking of this device, as Andreu Climent, co-founder and CEO of Corify Care, points out “is a significant milestone for us. It validates our commitment to providing innovative and non-invasive solutions for cardiac arrhythmias.”

Next Steps

Corify Care is committed to continuous innovation, and its next goal is to integrate the ACORYS mapping system into clinical practice, not only in Europe, but worldwide. Their next steps include obtaining FDA approval in the United States and expanding into other international markets. Corify Care also plans to develop ACORYS 2.0, incorporating digital twins and new clinical applications.

References

[1] Lippi, G., Sanchis-Gomar, F., Cervellin, G. (2021). Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. International Journal of Stroke, 16(2), 217-221.